European Journal of Cancer
Volume 45, Issue 1 , Pages 127-138 , January 2009

Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland

  • Rianne de Gelder

      Affiliations

    • Erasmus MC, Department of Public Health, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 10 4638456; fax: +31 10 4638474.
    • ,
  • Jean-Luc Bulliard

      Affiliations

    • Cancer Epidemiology Unit, Institute of Social and Preventive Medicine (IUMSP), University of Lausanne, Switzerland
    • ,
  • Chris de Wolf

      Affiliations

    • Agence Pour le Développement et évaluation des Politiques de Santé, Geneva, Switzerland
    • ,
  • Jacques Fracheboud

      Affiliations

    • Erasmus MC, Department of Public Health, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • Gerrit Draisma

      Affiliations

    • Erasmus MC, Department of Public Health, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • Doris Schopper

      Affiliations

    • Swiss Cancer League, Bern, Switzerland
    • ,
  • Harry J. de Koning

      Affiliations

    • Erasmus MC, Department of Public Health, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

Received 9 July 2008 ,Revised 17 September 2008 ,Accepted 25 September 2008.

References 

  1. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003;39(12):1718–1729
  2. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–1389
  3. Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol. 2008;19(6):1187–1194
  4. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990–8: comparison of observed with predicted mortality. BMJ. 2000;321(7262):665–669
  5. Olsen AH, Njor SH, Vejborg I, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ. 2005;330(7485):220
  6. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet. 2003;361(9367):1411–1417
  7. World Health Organization. Macroeconomics and health: investing in health for economic development: report of the Commission on Macroeconomics and Health. Geneva; 2001.
  8. Leivo T, Sintonen H, Tuominen R, Hakama M, Pukkala E, Heinonen OP. The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987–1992. Cancer. 1999;86(4):638–646
  9. Groenewoud JH, Otten JD, Fracheboud J, et al. Cost-effectiveness of different reading and referral strategies in mammography screening in the Netherlands. Breast Cancer Res Treat. 2007;102(2):211–218
  10. van Ineveld BM, van Oortmarssen GJ, de Koning HJ, Boer R, van der Maas PJ. How cost-effective is breast cancer screening in different EC countries?. Eur J Cancer. 1993;29A(12):1663–1668
  11. Swiss Cancer League. Swiss Cancer League Request “Reimbursement of screening mammography as a service of basic health insurance” to the Federal Office of Health. Bern; 2007.
  12. Neeser K, Szucs T, Bulliard J-L, Bachmann G, Schramm W. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors. Value Health. 2007;10(1):42–53
  13. Tabar L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1(8433):829–832
  14. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909–919
  15. van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer. 1990;66(7):1601–1612
  16. Warmerdam PG, de Koning HJ, Boer R, et al. Quantitative estimates of the impact of sensitivity and specificity in mammographic screening in Germany. J Epidemiol Commun Health. 1997;51(2):180–186
  17. Beemsterboer PM, de Koning HJ, Warmerdam PG, et al. Prediction of the effects and costs of breast-cancer screening in Germany. Int J Cancer. 1994;58(5):623–628
  18. Rijnsburger AJ, van Oortmarssen GJ, Boer R, et al. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. Int J Cancer. 2004;110(5):756–762
  19. National Evaluation Team for Breast cancer screening. National evaluation of breast cancer screening in the Netherlands – eleventh evaluation report. Rotterdam: Department of Public Health, Erasmus MC; 2005.
  20. Collette HJ, Day NE, Rombach JJ, de Waard F. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet. 1984;1(8388):1224–1226
  21. Collette HJ, de Waard F, Rombach JJ, Collette C, Day NE. Further evidence of benefits of a (non-randomised) breast cancer screening programme: the DOM project. J Epidemiol Commun Health. 1992;46(4):382–386
  22. Verbeek AL, Hendriks JH, Holland R, Mravunac M, Sturmans F, Day NE. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975–1981. Lancet. 1984;1(8388):1222–1224
  23. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer. 1989;63(1):181–187
  24. Tabar L, Vitak B, Chen HH, et al. The Swedish two-county trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38(4):625–651
  25. Michaelson JS, Silverstein M, Wyatt J, et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer. 2002;95(4):713–723
  26. Michaelson JS, Silverstein M, Sgroi D, et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer. 2003;98(10):2133–2143
  27. Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106(3):416–422
  28. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87(16):1217–1223
  29. Bjurstam N, Bjorneld L, Warwick J, et al. The Gothenburg breast screening trial. Cancer. 2003;97(10):2387–2396
  30. Bulliard J-L, De Landtsheer JP, Levi F. Results from the Swiss mammography screening pilot programme. Eur J Cancer. 2003;39(12):1761–1769
  31. Levi F, Te VC, la Vecchia C. Impact of mammography on breast cancer incidence in Vaud, Switzerland. J Natl Cancer Inst. 1991;83(16):1181–1182
  32. Bulliard J-L, Levi F. Evaluation épidémiologique du programme vaudois de dépistage du cancer du sein, 1999–2006. Lausanne: Raisons de santé; 2007. p. 136. <http://www.iumsp.ch/Publications/pub/rds136_fr.pdf>.
  33. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991;49(4):538–544
  34. Lynge E, Olsen AH, Fracheboud J, Patnick J. Reporting of performance indicators of mammography screening in Europe. Eur J Cancer Prev. 2003;12(3):213–222
  35. Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME, et al. Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy. Br J Cancer. 2004;90(2):383–392
  36. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer. 1991;49(4):531–537
  37. Organisation for Economic Co-operation and Development. Purchasing Power Parities Data, April 2007. <http://www.oecd.org/document/47/0,3343,en_2649_34357_36202863_1_1_1_1,00.html.
  38. Jeruss JS, Hunt KK, Xing Y, et al. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?. Cancer. 2006;107(10):2328–2336
  39. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996;
  40. Jonsson H, Nystrom L, Tornberg S, Lenner P. Service screening with mammography of women aged 50–69 years in Sweden: effects on mortality from breast cancer. J Med Screen. 2001;8(3):152–160
  41. Tornberg S, Carstensen J, Hakulinen T, Lenner P, Hatschek T, Lundgren B. Evaluation of the effect on breast cancer mortality of population based mammography screening programmes. J Med Screen. 1994;1(3):184–187
  42. van den Akker-van Marle ME, Reep-van den Bergh CM, Boer R, Del Moral A, Ascunce N, de Koning HJ. Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round. Int J Cancer. 1997;73(4):464–469
  43. Cronin KA, Feuer EJ, Clarke LD, Plevritis SK. Impact of adjuvant therapy, mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis. J Natl Cancer Inst Monogr. 1975;2006(36):112–121
  44. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98(11):774–782
  45. De Koning HJ. Breast cancer screening; cost-effective in practice?. Eur J Radiol. 2000;33(1):32–37
  46. Eurostat. Harmonised indices of consumer prices, 2008. <http://epp.eurostat.ec.europa.eu/portal/page?_pageid=2714,1,2714_61582043&_dad=portal&_schema=PORTAL>.
  47. Reserve Bank of Australia. Consumer Price Index, 2008. http://www.rba.gov.au/Statistics/Bulletin/G02hist.xls>.
  48. Bulliard JL, La Vecchia C, Levi F. Diverging trends in breast cancer mortality within Switzerland. Ann Oncol. 2006;17(1):57–59
  49. Smith-Bindman R, Ballard-Barbash R, Miglioretti DL, Patnick J, Kerlikowske K. Comparing the performance of mammography screening in the USA and the UK. J Med Screen. 2005;12(1):50–54
  50. Bihrmann K, Jensen A, Olsen AH, et al. Performance of systematic and non-systematic (‘opportunistic’) screening mammography: a comparative study from Denmark. J Med Screen. 2008;15(1):23–26
  51. Frede TE. Opportunistic breast cancer early detection in Tyrol, Austria 1996–2004. Is a mammography-screening program necessary?. Eur J Radiol. 2005;55(1):130–138
  52. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008;100(15):1082–1091
  53. Broeders MJ, Scharpantgen A, Ascunce N, et al. Comparison of early performance indicators for screening projects within the European Breast Cancer Network: 1989–2000. Eur J Cancer Prev. 2005;14(2):107–116
  54. International Monetary Fund. World Economic and Financial Surveys, World Economic Outlook Database, 2007. <http://www.imf.org>.

PII: S0959-8049(08)00747-8

doi: 10.1016/j.ejca.2008.09.015

European Journal of Cancer
Volume 45, Issue 1 , Pages 127-138 , January 2009

Article Tools

* Image Usage & Resolution